J&J Gets Label Expansion – Analyst Blog
Zacks Market Commentaries (August 3rd, 2009) Writes:
Last week, Johnson & Johnson (JNJ) announced the marketing approval of Invega extended-release tablets either for solo use or in combination with mood stabilizers and antidepressants for treating schizoaffective disorder. The disorder results in symptoms similar to schizophrenia in addition to mania or depression.
On the same day, the US agency gave its nod of approval to Invega Sustenna -- a once-monthly, injectable version of Invega to treat schizophrenia in adults. It will be marketed in the US by Janssen, a unit of Johnson & Johnson.
Invega Sustenna has been developed using the proprietary technology NanoCrystal Technology, which is a registered trademark of Elan Pharma International Ltd, Ireland, a subsidiary of Elan Corp. plc (ELN). The FDA approved the drug on the basis of two international, randomized, double-blind placebo-controlled studies of schizoaffective disorder patients with acute symptoms.
Approximately, one percent of the world’s population suffers from schizophrenia, which prevents a person
...bipolar disorder, December;, Depression, Elan Corp. plc, Elan Pharma International Ltd, Fda, INVEGA, Invega extended-release tablets, Ireland, Johnson & Johnson, mania, Market Commentary, schizoaffective disorder, schizophrenia, Stocks to Watch, technology NanoCrystal Technology, United States, USD, Zacks Market Commentaries


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)





Gold investors know all too well the psychological importance of $1,000 gold. The yellow metal’s been hovering frustratingly near that level for weeks after briefly surpassing it in February. According to John Kaiser, editor of the Kaiser Bottom-Fishing Report, “we’re getting very close.” In this exclusive interview with The Gold Report, John shares his “modest” price forecast of $1,300 – $1,400 within the next six months and presents strategies for gold companies looking to create value.

